走进利拉鲁肽 更多 >>
继日本中央社会保险医疗委员会批准了Victoza®（利拉鲁肽）的定价之后，诺和诺德制药公司计划将尽快在当地市场推出这种产品。诺和诺德表示，Victoza®是首个在日本获准上市的GLP-1类药物，既可以单独用药，也可以作为辅助药物与磺脲类降糖药(SU)联用。
肝门静脉内GLP-1受体与人体进食调节无关
研究显示，GLP抑制食欲的作用在GLP-1被注射到中枢神经系统的时候是最明显的，但是外周摄取GLP-1也能起到抑制食欲效果。近期多项研究提示，门静脉内调节糖代谢的外周神经可以被GLP-1激活。
为了验证肝门静脉内神经末梢的GLP-1受体对进食的影响，该研究比较了肝门静脉注射GLP-1及颈静脉注射GLP-1的差别。研究结果显示，虽然外周GLP-1可以调节进食，但是与分布于肝门静脉上迷走神经上的GLP-1受体无关。
A wide range of evidence points to a role for GLP-1 to regulate food intake. Anorectic effects of GLP-1 are most apparent when the peptide is administered directly into the central nervous system (CNS), but suppression of food intake has also been noted in some cases with peripheral administration. It is unclear which GLP-1 receptor (GLP-1r) population mediates the effects of plasma GLP-1, although direct actions to activate CNS neurons have been demonstrated. More recently several groups have demonstrated that GLP-1 can activate peripheral nerves in the hepatic portal vein to regulate glucose metabolism.
To test the hypothesis that GLP-1 receptors on nerve terminals in the hepatic portal affect feeding behavior, we compared the effects of direct infusions into hepatic portal and jugular veins in rats. Jugular GLP-1 decreased food intake at doses as low as 10 μg from 0.5–4 h into the dark cycle, whereas portal GLP-1 decreased food intake only at the highest dose tested (100 μg). The blockade of endogenous GLP-1 action before or during eating by infusing dH-Ex, GLP-1 receptor antagonist, into either jugular or portal vein did not cause any change in food intake during either the dark or light cycles. Taken together, these data suggest that while peripheral GLP-1 may be involved in the regulation of food intake, the key GLP-1 receptors are unlikely to be those associated with vagal afferent nerves innervating the hepatic portal vein.
编辑: helen
以下网友留言只代表网友个人观点，不代表网站观点
